20(S)-protopanaxadiol decreases atherosclerosis in the ApoE KO mice by increasing the levels of LDLR and inhibiting its binding with PCSK9

Ye-Wei Huang,Meng Zhang,Yan Nie,Jun Sheng,Litian Wang,JinBo Yang,Wen Luer Meng,Xuanjun Wang

DOI: https://doi.org/10.1039/d2fo00392a

2022-05-13

Abstract:Chinese medicinal and edible plants such as Panax notoginseng and ginseng are widely used for the treatment of Atherosclerosis (AS). AS is the main pathological basis of cardiac-cerebral vascular disease, which seriously threatens human health and quality of life. Low-density lipoprotein (LDL) is the main pathogenic factor of AS. LDL receptor (LDLR) is an important protein that functions to mediate the uptake and degradation of plasma LDL. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) can mediate the internalization and degradation of LDLR. So, increasing LDLR level by inhibiting PCSK9 is one of the important means of prevention and treatment of AS. In this study, by combining the interaction technology (Surface plasmon resonance, SPR) of small molecule compounds with membrane receptor protein, cell experiment, and in vivo experiment, it was originally proved that 20(S)-protopanaxadiol (PPD), as a hydrolytic product of Panax notoginseng saponins in the intestinal tract, can bind to the extracellular domain of LDLR and inhibit the role of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in mediating LDLR degradation. The results showed that PPD significantly reduced aortic plaques and hepatic steatosis in the HFD-fed ApoE KO mice. LDLR protein levels were elevated in the liver tissues isolated from PPD-treated HFD-fed ApoE KO mice and PPD-treated HepG2 cells. Our findings demonstrated that PPD significantly increased LDLR level and reduced AS in the HFD-fed ApoE KO mice on account of the LDLR degradation can be inhibited by PPD inhibiting the interactions between PCSK9 and LDLR.

biochemistry & molecular biology,food science & technology